Payment overview · 2025
General Payments
$529.15
20 reported records · 12 companies
Healthcare provider profile · identity verified
William A Shade
Allopathic & Osteopathic Physicians|Internal Medicine · ZANESVILLE, OH · NPI 1104816321
Verified facts
What the public records show
CMS Open Payments records show William A Shade received $529.15 in general payments during 2025 across 20 reported records.
Edwards Lifesciences Corporation accounted for 25.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Gemtesa, Qulipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 193 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 554 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $132.72 | 25.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $109.62 | 20.7% | 5 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $69.68 | 13.2% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $48.27 | 9.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $30.09 | 5.7% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $27.13 | 5.1% | 1 | 2025 |
| QOL Medical, LLC | Unresolved — no canonical attribution shown | $25.90 | 4.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.18 | 4.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.22 | 3.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.90 | 3.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.07 | 2.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $14.37 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $529.15 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $132.72 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $80.54 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $69.68 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $54.98 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $48.27 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $30.09 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $29.08 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $27.13 | 1 | 2025 |
Source payment records
|
|||||
| Sucraid Normalized: sucraid |
Drug | QOL Medical, LLC | $25.90 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.18 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $17.22 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.90 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.07 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.07 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.07 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $14.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 193 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
47 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
50 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
88 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
61 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
160 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
92 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
193 | 192 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
554 | 79 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 15 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1245 | 273 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1032 | 203 |
| Potassium Chloride | Potassium Chloride | 802 | 144 |
| Metoprolol Succinate | Metoprolol Succinate | 683 | 146 |
| Furosemide | Furosemide | 669 | 150 |
| Losartan Potassium | Losartan Potassium | 665 | 148 |
| Trazodone Hcl | Trazodone Hcl | 568 | 101 |
| Eliquis | Apixaban | 554 | 79 |
| Lisinopril | Lisinopril | 547 | 112 |
| Pantoprazole Sodium | Pantoprazole Sodium | 523 | 131 |
| Amlodipine Besylate | Amlodipine Besylate | 504 | 118 |
| Metformin Hcl | Metformin Hcl | 475 | 93 |
| Gabapentin | Gabapentin | 460 | 88 |
| Metoprolol Tartrate | Metoprolol Tartrate | 445 | 89 |
| Sertraline Hcl | Sertraline Hcl | 436 | 66 |
| Omeprazole | Omeprazole | 397 | 106 |
| Tamsulosin Hcl | Tamsulosin Hcl | 381 | 84 |
| Carvedilol | Carvedilol | 331 | 65 |
| Hydrochlorothiazide | Hydrochlorothiazide | 305 | 77 |
| Famotidine | Famotidine | 263 | 52 |
| Januvia | Sitagliptin Phosphate | 262 | 25 |
| Alprazolam | Alprazolam | 259 | 54 |
| Simvastatin | Simvastatin | 248 | 57 |
| Duloxetine Hcl | Duloxetine Hcl | 244 | 47 |
| Citalopram Hbr | Citalopram Hydrobromide | 238 | 50 |
| Montelukast Sodium | Montelukast Sodium | 229 | 64 |
| Xarelto | Rivaroxaban | 226 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 217 | 55 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 212 | 149 |
| Prednisone | Prednisone | 208 | 91 |
| Ondansetron Hcl | Ondansetron Hcl | 201 | 52 |
| Allopurinol | Allopurinol | 200 | 46 |
| Clopidogrel | Clopidogrel Bisulfate | 197 | 42 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 193 | 192 |
| Mirtazapine | Mirtazapine | 188 | 49 |
| Donepezil Hcl | Donepezil Hcl | 186 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 186 | 45 |
| Quetiapine Fumarate | Quetiapine Fumarate | 183 | 24 |
| Buspirone Hcl | Buspirone Hcl | 182 | 46 |
| Fluoxetine Hcl | Fluoxetine Hcl | 172 | 31 |
| Ezetimibe | Ezetimibe | 170 | 37 |
| Meloxicam | Meloxicam | 166 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 165 | 36 |
| Jardiance | Empagliflozin | 160 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 160 | 40 |
| Baclofen | Baclofen | 157 | 35 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 157 | 25 |
| Lamotrigine | Lamotrigine | 156 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 155 | 45 |
| Warfarin Sodium | Warfarin Sodium | 154 | 25 |
| Levetiracetam | Levetiracetam | 144 | 23 |
| Divalproex Sodium | Divalproex Sodium | 143 | 20 |
| Spironolactone | Spironolactone | 139 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 137 | 45 |
| Ozempic | Semaglutide | 136 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 130 | 27 |
| Memantine Hcl | Memantine Hcl | 128 | 25 |
| Alendronate Sodium | Alendronate Sodium | 127 | 32 |
| Lovastatin | Lovastatin | 124 | 31 |
| Ropinirole Hcl | Ropinirole Hcl | 122 | 26 |
| Paroxetine Hcl | Paroxetine Hcl | 120 | 25 |
| Clonidine Hcl | Clonidine Hcl | 119 | 26 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 117 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 115 | 52 |
| Finasteride | Finasteride | 115 | 29 |
| Sucralfate | Sucralfate | 115 | 22 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 112 | 17 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 112 | 15 |
| Atenolol | Atenolol | 110 | 27 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 105 | 32 |
| Torsemide | Torsemide | 104 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 95 | 28 |
| Trulicity | Dulaglutide | 92 | 17 |
| Latanoprost | Latanoprost | 88 | 12 |
| Myrbetriq | Mirabegron | 88 | 11 |
| Tramadol Hcl | Tramadol Hcl | 87 | 18 |
| Divalproex Sodium Er | Divalproex Sodium | 85 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 85 | 25 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 84 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 84 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 81 | 61 |
| Humalog Kwikpen U-100 | Insulin Lispro | 81 | 13 |
| Oxcarbazepine | Oxcarbazepine | 80 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 79 | 17 |
| Nystatin | Nystatin | 79 | 32 |
| Carbamazepine | Carbamazepine | 75 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 75 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 73 | 21 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 72 | 29 |
| Lactulose | Lactulose | 69 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 68 | 12 |
| Metformin Hcl Er | Metformin Hcl | 67 | 22 |
| Aripiprazole | Aripiprazole | 66 | 12 |
| Bupropion Xl | Bupropion Hcl | 66 | 20 |
| Farxiga | Dapagliflozin Propanediol | 61 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 61 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 61 | 12 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 61 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 60 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 60 | suppressed |
| Cephalexin | Cephalexin | 57 | 38 |
| Lorazepam | Lorazepam | 56 | 17 |
| Perphenazine | Perphenazine | 55 | suppressed |
| Risperidone | Risperidone | 55 | 11 |
| Albuterol Sulfate | Albuterol Sulfate | 54 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 54 | 12 |
| Cholestyramine | Cholestyramine (With Sugar) | 54 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 54 | 23 |
| Tradjenta | Linagliptin | 54 | suppressed |
| Glimepiride | Glimepiride | 53 | 12 |
| Nifedipine Er | Nifedipine | 52 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 51 | 13 |
| Lansoprazole | Lansoprazole | 51 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 50 | 16 |
| Synthroid | Levothyroxine Sodium | 50 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 49 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 48 | 43 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 47 | 14 |
| Ibuprofen | Ibuprofen | 47 | 17 |
| Linzess | Linaclotide | 47 | 11 |
| Olanzapine | Olanzapine | 47 | suppressed |
| Ondansetron Odt | Ondansetron | 47 | 23 |
| Fluconazole | Fluconazole | 46 | 34 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 25 |
| Amoxicillin | Amoxicillin | 43 | 17 |
| Gemfibrozil | Gemfibrozil | 43 | suppressed |
| Levofloxacin | Levofloxacin | 43 | 33 |
| Metronidazole | Metronidazole | 43 | 26 |
| Clonazepam | Clonazepam | 42 | 11 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 42 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 40 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 40 | suppressed |
| Pregabalin | Pregabalin | 40 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 11 |
| Lithium Carbonate | Lithium Carbonate | 38 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | suppressed |
| Anastrozole | Anastrozole | 37 | suppressed |
| Hydrocortisone | Hydrocortisone | 36 | 14 |
| Solifenacin Succinate | Solifenacin Succinate | 36 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 35 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 35 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 35 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 34 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| Valsartan | Valsartan | 33 | 11 |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 32 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 32 | suppressed |
| Methylprednisolone | Methylprednisolone | 32 | 29 |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 31 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Glipizide | Glipizide | 31 | 11 |
| Phenytoin | Phenytoin | 31 | suppressed |
| Scopolamine | Scopolamine | 31 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 31 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 30 | suppressed |
| Haloperidol | Haloperidol | 30 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 30 | 11 |
| Bumetanide | Bumetanide | 29 | suppressed |
| Celecoxib | Celecoxib | 29 | suppressed |
| Acyclovir | Acyclovir | 28 | 13 |
| Amiloride-Hydrochlorothiazide | Amiloride/Hydrochlorothiazide | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | suppressed |
| Mupirocin | Mupirocin | 27 | 13 |
| Prednisolone Acetate | Prednisolone Acetate | 27 | suppressed |
| Sotalol | Sotalol Hcl | 27 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 27 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Dofetilide | Dofetilide | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 25 | suppressed |
| Klor-Con M20 | Potassium Chloride | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | 21 |
| Prazosin Hcl | Prazosin Hcl | 25 | suppressed |
| Primidone | Primidone | 25 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 19 |
| Budesonide | Budesonide | 24 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 24 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 17 |
| Azelastine Hcl | Azelastine Hcl | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Ketoconazole | Ketoconazole | 23 | 15 |
| Acetic Acid | Acetic Acid | 22 | suppressed |
| Estradiol | Estradiol | 22 | 11 |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 21 | 21 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 21 | 21 |
| Colchicine | Colchicine | 21 | 15 |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Zonisamide | Zonisamide | 20 | suppressed |
| Cefdinir | Cefdinir | 19 | 17 |
| Methenamine Hippurate | Methenamine Hippurate | 19 | suppressed |
| Promacta | Eltrombopag Olamine | 19 | suppressed |
| Sodium Bicarbonate | Sodium Bicarbonate | 19 | suppressed |
| Tresiba | Insulin Degludec | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 16 |
| Colestipol Hcl | Colestipol Hcl | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 18 | suppressed |
| Meropenem | Meropenem | 18 | suppressed |
| Novolog | Insulin Aspart | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Arformoterol Tartrate | Arformoterol Tartrate | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 17 | suppressed |
| Carbamazepine Er | Carbamazepine | 17 | suppressed |
| Loxapine | Loxapine Succinate | 17 | suppressed |
| Ofloxacin | Ofloxacin | 17 | suppressed |
| Rivastigmine | Rivastigmine | 17 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Dulera | Mometasone/Formoterol | 16 | suppressed |
| Gemtesa | Vibegron | 16 | suppressed |
| Nyamyc | Nystatin | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 15 |
| Xifaxan | Rifaximin | 16 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 15 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Insulin Degludec Pen (U-200) | Insulin Degludec | 15 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 15 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 15 | suppressed |
| Procrit | Epoetin Alfa | 15 | suppressed |
| Prolia | Denosumab | 15 | suppressed |
| Qulipta | Atogepant | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 14 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 14 | suppressed |
| Maxalt Mlt | Rizatriptan Benzoate | 14 | suppressed |
| Mesalamine | Mesalamine | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Cabergoline | Cabergoline | 13 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Methadone Hcl | Methadone Hcl | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 13 | 11 |
| Striverdi Respimat | Olodaterol Hcl | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 12 | 11 |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Dexilant | Dexlansoprazole | 12 | suppressed |
| Effer-K | Potassium Bicarbonate/Cit Ac | 12 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Insulin Aspart | Insulin Aspart | 12 | suppressed |
| Levemir | Insulin Detemir | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $529.15 · 20 records | Edwards Lifesciences Corporation | ABRYSVO, AIRSUPRA, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), GEMTESA, KISUNLA, PREVNAR 20, QULIPTA, Sucraid, UBRELVY, VRAYLAR, Veozah, WATCHMAN Access System | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error